Drug intelligence / Profile preview

Zubsolv

Development stage: Approved
Lead developer: Orexo
Modality: Drug Delivery Systems
Administration: Sublingual

Overview

Zubsolv is a prescription medication that combines buprenorphine and naloxone in sublingual tablet form, used for the treatment of opioid dependence. It's designed to be part of a complete treatment program that includes counseling and behavioral therapy. The sublingual tablet dissolves under the tongue, typically within 5 minutes. If multiple tablets are required, they should be placed in different areas under the tongue simultaneously. The medication should not be swallowed or chewed for proper absorption.

Brand names: Zubsolv
Other names: buprenorphine + naloxonebuprenorphine/naloxone

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Zubsolv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zubsolv.

Explore the full profile